FDA Advisory Committee to Review Investigational Sotagliflozin as Potential Treatment for Type 1 Diabetes

Lexicon Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) plans to review Lexicon collaborator Sanofi’s New Drug Application (NDA) for sotagliflozin, an i https://globenewswire.com/news-release/2018/11/29/1659016/0/en/FDA-Advisory-Committee-to-Review-Investigational-Sotagliflozin-as-Potential-Treatment-for-Type-1-Diabetes.html